publication . Article . 2008

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia

Bossie, Cynthia;
Open Access English
  • Published: 10 Oct 2008 Journal: Neuropsychiatric Disease and Treatment (issn: 1178-2021, Copyright policy)
  • Publisher: Dove Press
Ibrahim Turkoz, Cynthia A Bossie, Bryan Dirks, Carla M CanusoOrtho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USAAbstract: Direct and indirect effects of the new psychotropic paliperidone extended-release (paliperidone ER) tablets on negative symptom improvement in schizophrenia were investigated using path analysis. A post hoc analysis of pooled data from three 6-week, double-blind, placebo-controlled studies of paliperidone ER in patients experiencing acute exacerbation was conducted. Regression analysis explored relationships between baseline/study characteristics and negative symptoms. Change in Positive and Negative Syndrome Scale (PANSS) negat...
Persistent Identifiers
free text keywords: Neuropsychiatric Disease and Treatment
28 references, page 1 of 2

Andreasen NC. 1982. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry, 39:784-8. [OpenAIRE]

Ayuso-Gutierrez JL, del Rio Vega JM. 1997. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res, 28:199-206. [OpenAIRE]

Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry, 154:672-6.

Carpenter WT Jr, Heinrichs DW, et al. 1985. Treatment of negative symptoms. Schizophr Bull, 11:440-52. [OpenAIRE]

Davidson L, McGlashan TH. 1997. The varied outcomes of schizophrenia. Can J Psychiatry, 42:34-43.

Davidson M, Emsley R, Kramer M, et al. 2007. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res, 93:117-30.

Docherty JP, Grogg AL, Kozman C, et al. 2002. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. American College of Neuropsychopharmacology 41st Annual Meeting; San Juan, Puerto Rico. December 8-12.

Gharabawi G, Bossie C, Turkoz I, et al. 2007. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Mental Dis, 195:976-82.

Guy WA. 1972. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare. p. 533-7.

Guy WA. 1976. Clinical global impressions. In: ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare. p. 218-222.

Kane J, Canas F, Kramer M, et al. 2007. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res, 90:147-61.

Kay SR, Fiszbein A, Opler LA. 1987. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull, 13:261-76. [OpenAIRE]

King DJ. 1998. Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol, 8:33-42.

Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. 2006. The NIMHMATRICS consensus statement on negative symptoms. Schizophr Bull, 32:214-9.

Leucht S, Pitschel-Walz G, Abraham D, et al. 1999. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res, 35:51-68. [OpenAIRE]

28 references, page 1 of 2
Any information missing or wrong?Report an Issue